Who is sponsoring NCT03536598?

NCT03536598 is sponsored by HK inno.N Corporation.

What drugs are being tested in NCT03536598?

Interventions in NCT03536598: Amlodipine 10 mg + Valsartan 160 mg + Rosuvastatin 20 mg, Amlodipine 10 mg + Valsartan 160 mg, Valsartan 160 mg + Rosuvastatin 20 mg.

What condition does NCT03536598 study?

NCT03536598 studies Hypertension With Hyperlipidemia.

Is NCT03536598 still recruiting?

NCT03536598 is currently completed. Last updated 30 May 2018.

Last reviewed 2018-05-30 · How we verify

NCT03536598

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study to Evaluate the Safety and Efficacy of CJ-30060 in Hypertensive Patients With Hyperlipidemia

Completed Phase 3 Last updated 30 May 2018

What this trial tests

Phase 3 trial testing Amlodipine 10 mg + Valsartan 160 mg + Rosuvastatin 20 mg in Hypertension With Hyperlipidemia in 203 participants. Completed in 4 September 2017.

Timeline

14 October 2016

Primary endpoint
4 September 2017

4 September 2017

Quick facts

Lead sponsor	HK inno.N Corporation
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	203
Start date	14 October 2016
Primary completion	4 September 2017
Estimated completion	4 September 2017

Drugs / interventions tested

Amlodipine 10 mg + Valsartan 160 mg + Rosuvastatin 20 mg — full drug profile →
Amlodipine 10 mg + Valsartan 160 mg — full drug profile →
Valsartan 160 mg + Rosuvastatin 20 mg — full drug profile →

Conditions studied

Hypertension With Hyperlipidemia — all drugs for Hypertension With Hyperlipidemia →

Sponsor

HK inno.N Corporation — full company profile →

Who can join

Adults 19 to 74, any sex, with Hypertension With Hyperlipidemia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To evaluate the safety and efficacy of CJ-30060 compared with amlodipine/valsartan combination therapy and valsartan/rosuvastatin combination therapy in hypertensive patients with hyperlipidemia

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other HK inno.N Corporation trials

Trials by the same sponsor.

NCT07277712 — A Study to Evaluate the Pharmacokinetics and Food-effect of IN-M00002 Tablet in Healthy Adult Volunteers · Phase 1 · not yet recruiting
NCT07192263 — Study to Evaluate the Efficacy and Safety of IN-B00009 Injection in Adults With Obesity or Overweight Without Diabetes M · Phase 3 · not yet recruiting
NCT06736912 — This Study Aims to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties and Food Effect of · Phase 1 · not yet recruiting
NCT06725355 — To Compare the Pharmacokinetics and Safety After a Single Dose Administration of IN-G00002 and IN-R00002 in Healthy Adul · Phase 1 · active not recruiting
NCT06332638 — PK, PD and Safety of Tegoprazan 12.5 mg After Oral Administration in Healthy Subjects · Phase 1 · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03536598 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by HK inno.N Corporation
Last refreshed: 30 May 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03536598.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing